ResMed (RMD) PT Raised to $200 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $229.94 --0%
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Rating Summary:
12 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 19 | New: 16
Join SI Premium – FREE
RBC Capital analyst Craig Wong-Pan raised the price target on ResMed (NYSE: RMD) to $200.00 (from $187.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Canaccord Downgrades ResMed (RMD) to Hold
- Minerva SA (BEEF3:BZ) PT Lowered to R$3.90 at Goldman Sachs
- ResMed (RMD) PT Raised to $270 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
